Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021

Dario Trapani, Giuseppe Curigliano

European Institute of Oncology, IRCCS, Milan, Italy
Department of Oncology and Hematology, University of Milan, Milan, Italy

ABSTRACT

Metastatic triple-negative breast cancer (mTNBC) is associated with an aggressive disease course, and limited treatment options. The recent accelerated drug development in the space of mTNBC has been driven by a precision-medicine approach, with the potential to deliver more personalized treatments and result in better outcomes. Antibody-drug conjugates (ADCs) have introduced a novel paradigm in the space of mTNBC, leading to the approval of the first targeted agent in this setting. The research and development of ADCs comes in parallel with the identification of tumor-specific targets of pharmacological interest. As a result, ADCs bring the potential for agnostic treatment delivery across multiple histology types, and theranostically, by coupling tumor-antigen identification and treatment, as a continuum. In this perspective, recent progress in ADCs development for early and mTNBC are outlined, in the trade-off of patient selection, tumor specificity, precise drug delivery, potent payloads safety and quality of life.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast tumors, associated with dismal prognosis [1,2]. Innovative treatments have expanded the therapeutic options for selected patients with advanced disease (mTNBC). Inter alia, the new class of molecules of antibody-drug conjugates (ADCs) has rapidly positioned in the setting of mTNBC, providing significant benefits in pretreated patients [3]. With the advent of ADCs, progress has been marked in targeting TNBC [4]. Tackling this ‘un-targetable’ tumor type has been the real enterprise of the last years, overcoming the original sin of classification of TNBC in a default ‘non-positive’ category, ultimately grouping together a spectrum of heterogeneous diseases [1]. As such, ADCs have opened an ‘identity crisis’ for TNBC treatments [3]. These molecules are composed of a backbone of monoclonal antibody (MAb), exploiting the best role they are engineered for: recognize antigens. But ADCs are linked to cytotoxic payloads, resulting in tailored delivery of highly active agents, with the intent to spare non-targeted tissues [3]. At the end, they interpret essentially a new pharmacological delivery model to treat tumors [3,4].

The implementation of ADCs has first modernized the view on MAb clinical utilization: not really only to switch-off hyperactive tumorigenic signaling; ADCs can exert anti-neoplastic activities in disregard of the biologic functions of their pharmacological receptors: antigens are linked, payloads are released, cancer cells are killed via internalized chemotherapies [3]. Such a change in perspective implies that: (i) ADCs can exploit activity across multiple tumor types – delivering agnostically, based on antigen expressions; (ii) ADCs offer an attractive perspective for treatment personalization, based on the multiple targetable antigens that can be identified in a single patient - a possible declination of the theranostic paradigm. Agnosticity and theranosticity, however, will be reached only with an optimal trade-off between antibody specificity – to avoid off-target effects and non-specific activity related to the release of the payload in the bloodstream – and patient tolerance of the cumulative toxicities. Pursuing precision in this context will require understanding better how these new ADCs tailor the targets; perhaps, most importantly, there must be better knowledge on what is the minimal amount of membrane antigen to
be expressed, to determine ADCs efficacy, and if traditional techniques like immuno-histochemistry are sensitive enough for this purpose. Table 1

The experience of ADCs in mTNBC is interesting. The first ADCs approved in the USA for mTNBC is sacituzumab govitecan, a mAb targeting trophoblast cell-surface antigen 2 (Trop-2) and linked to the active metabolite of irinotecan (SN-38) [5]. Sacituzumab govitecan has positioned in a setting of high clinical unmet need, resulting in a benefit for patients with pretreated mTNBC, when compared with standard care of treatment plans. The phase 3 pivotal trial ASCENT included women after two or more lines of therapy for mTNBC [5]. The first analysis reported an improvement of the progression-free (PFS) and overall-survival (OS), with a median gain of +3.9 months (hazard ratio [HR], 0.41; P < 0.0001) and +5.4 months (HR, 0.48; P < 0.0001), respectively. Toxicity profile was non-trivial, as some systemic cytotoxic effects were observed, including a half of patients experiencing moderate-severe neutropenia and 6% with febrile events. Trop-2 is largely expressed in tumor cells, including non-mTNBC tumors, and clinical activity has been reported across a spectrum of Trop-2 positive diseases [4].

The clinical implementation of ADCs anti-HER2 has reshaped the perspectives in HER2 targetability, and paved new opportunities to treat also mTNBC patients [6]. While HER2 overexpression has been related to an oncogene addiction of a quarter of breast cancers (i.e., HER2-positive). HER2 can also be expressed in the cell membranes in the absence of gene amplifications (i.e., HER2-low): it is estimated that a half of patients presents a HER2-low [6]. Although preliminary, anti–HER2 ADCs have provided some activity for HER2-low mTNBC in early-phase clinical trials, including with the ADCs Trastuzumab deruxtecan and Trastuzumab duocarmazine. With these anti–HER2 ADCs, objective response rates (ORR) in the HER2-low patients ranged between 28 and 40%, with a median PFS of 11.1 moths [5,6]. Similar findings have been reported with other targets, like the anti–HER3 ADC Patriotumab deruxtecan, reporting 13–33% ORR, and the anti–Liv1 Ladiratuzumab vedotin, with 29% ORR [7].

The identification of cancer-specific antigens has resulted ultimately in a flareup of new ADCs under development, aiming at refining the patient selection, thus offering specific and potentially single-patient tailored treatments [4,7]. As a paradox, the ‘untargetable’ setting of TNBC is flourishing with a plethora of targeted molecules. Table 2.

Translating new paradigms of care from the lessons learnt in the advanced setting of care is not only important but can boost the benefits for patients [8]. Therefore, when a drug shows activity in resistant diseases and improvement of the survival, there is rationale to understand what impact can be derived in the early setting [8]. This could be the case of some ADCs: as new data will emerge from ongoing trials, the incorporation of these agents in the high-risk early setting is timely expected.

Tumors resistant to neoadjuvant treatments (NAT) do not completely regress, namely do not reach a pathological complete response (pCR). Post-NAT non-pCR status is prognostically unfavorable [9].

The loss of HER2-overexpression, including the switch from HER2-positive to HER2-low, has been described as a mechanism of resistance emerging during NAT, in patients receiving anti-HER2 therapies, without pCR – resulting in resistance to adjuvant trastuzumab [9,10]. However, when non-pCR patients receive an escalated treatment with the ADCs trastuzumab emtansine, including in the cases of switch to HER2-low or HER2-negative in the residual disease, prognosis appears improved [10]. Thus, features of the residual disease can portend therapeutic implications. Then, ADCs can be strategic to tailor high-risk diseases, presenting dynamic heterogeneities matured and/or revealed under NAT

### Table 1

| Name                        | Target antigen | Payload | DAR | Indication                      | EMA approval | FDA approval |
|-----------------------------|----------------|---------|-----|---------------------------------|--------------|--------------|
| Brentuximab vedotin<sup>1</sup> | CD30           | MMAE    | -4 | CD30-positive HL, Rel/Ref sALCL, CD30-positive TCL | 2012         | 2011         |
| Trastuzumab emtansine<sup>1</sup> | HER2           | DM1     | 3.5 | HER2-positive mBC, HER2-positive eBC | 2013         | 2013         |
| Inotuzumab ozogamicin<sup>2</sup> | CD22           | Calicheamicin | -4 | Relapsed/refractory B-cell precursor ALL | 2017         | 2017         |
| Gemtuzumab ozogamicin<sup>3</sup> | CD33           | Calicheamicin | 2–3 | CD33-positive AML | 2018         | 2017         |
| Moxetumomab pasudotox<sup>4</sup> | CD22           | PE38    | 1  | Rel/Ref HCL                | ODD (2008)   | 2013         |
| Polatuzumab vedotin<sup>5</sup> | CD79b          | MMAE    | 3.5 | Rel/Ref DLirclo         | 2020         | 2019         |
| Loncastuximab tesirine<sup>6</sup> | CD19           | Tesirine | 2.3 | Rel/Ref DLirclo         | ODD (2021)   | 2021         |
| Belantamab mafodotin<sup>7</sup> | BCMA           | mcMMAF  | -4 | Rel/Ref MM              | 2020         | 2020         |
| Trastuzumab deruxtecan<sup>8</sup> | HER2           | DXd     | 7–8 | HER2-positive mBC | 2021         | 2019         |
| Enfortumab Vedotinc<sup>9</sup> | Nectin4        | MMAE    | 3.8 | mUC                  | 2021         | 2019         |
| Sacituzumab govitecan<sup>10</sup> | TROP2         | SN-38   | 7.6 | mTNBC               | 2021         | 2020         |

EMA and FDA year of approval are intended for the first approval. MMAE and DM1 are tubulin polymerisation inhibitor. Calicheamicin is a double-strand DNA break inducing agent. DXd and SN-38 are DNA topoisomerase I inhibitor. PE38 is an inhibitor of the protein synthesis. Tesirine is a DNA cross-linking agent. DAR, drug-to-antibody ratio. EMA, European Medicines Agency. FDA, US Food and Drug Administration. MMAE, Monomethyl auristatin E. DM1, mertansine. PE38, 38 kDa truncated portion of the Pseudomonas exotoxin A. McMMAF, Maleimidocaproyl monomethylauristatin F. DXd, exatecan derivative DXd. SN-38, 7-ethyl-10-hydroxy camptothecin. HER2, human epidermal growth factor receptor 2. BCMA, B-cell maturation antigen. TROP2, trophoblast cell surface protein 2. HL, Hodgkin lymphoma (multiple setting). sALCL, adult systemic anaplastic large cell lymphoma. TCL, T-cell cutaneous lymphoma. mBC, metastatic breast cancer. eBC, early breast cancer. ALL, acute lymphoblastic leukemia. AML, acute myeloid leukemia. HCL, hairy cell leukemia. DBCL, diffuse large B-cell lymphoma. MM, multiple myeloma. mUC, metastatic urothelial cancer. mTNBC, metastatic triple-negative breast cancer. Rel/Ref, relapsed/refractory. ODD, orphan drug designation.

<sup>1</sup> Used in combination with chemotherapy.

<sup>2</sup> Used with chemotherapy and another monoclonal antibody.

<sup>3</sup> Used as a single agent.
The bio-selection of patients is critical to understand the need for escalation of treatments, and the opportunity to incorporate new effective agents in the settings of high unmet need. A pCR-triggered enrollment in clinical trials to escalated treatments can benefit patients with more resistant tumors (i.e., using therapeutic sensitivity), for whom novel strategies can impact on the predictable adverse disease trajectory. A pCR-driven approach has demonstrated to enrich the populations of women deriving benefits from adjunctive therapies, also in the setting of HER2-negative tumors. Such a bio-selection has resulted in the clinical uptake of post-neoadjuvant capcetabine and prompted a number of clinical trials ongoing. On the same page, one must carve the results of Olaparib in patients with germlal BRCA mutations and no-pCR after NAT. In summary, ADCs can be instrumental in the early setting, to precisely tailor proved resistant tumors (e.g., no pCR after NAT) expressing membrane antigens deemed adequate and safe pharmacological targets. Currently, the clinical trials SASCIA (NCT04595565, phase 3) and ASPRIA (NCT04434040, phase 2, with atezolizumab) are testing the role of sacituzumab govticecan in the post-NAT non-pCR setting, compared with the standard adjuvant capcetabine, platinum salts, or observation. With invasive-disease free survival as primary endpoint and OS, safety, compliance, and patient reported outcomes as secondary endpoints, SASCIA trial is expected to be completed by 2026–2028. Advancements in the clinical research will happen with improvement of the understanding of endpoints capable both to track disease trajectory-modifying interventions and include the domains of patient-relevant metrics. The position of ADCs for early TNBC is not around corner, and clinical trials will elucidate how to optimize the treatments. Therefore, the identification of patient-level prognosticators is highly desirable, to refine the selection, and escalate in the precise subset at very high-risk, sparing patients with good prognosis. The discussion around new targets, new drugs and benefits can never be disassociated from the dialogue on patient-level prognostic factor - and pCR is far to be a perfect prognosticator, thought presently very useful.

In the complex landscape of patient-level priorities and new drugs development, ADCs will likely help improve the treatment personalization, providing an option in the high-risk setting, based on dynamic tumor characteristics. Presently, understanding the changes in the tumor biology in the early treatment setting is a way to improve the overall outcome, and result in higher curative rates.

### Funding source

None.

### Declaration of competing interest

GC has received honoraria from Pfizer, Novartis, Lilly, Roche; fees for expert testimony and medical education from Pfizer; and has participated in advisory board s for Pfizer, Roche, Lilly, Novartis, Seattle Genetics, Celltrion. All the declarations are outside the submitted work. DT declares no COI.

### References

1. Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. Oct 16 NPJ Breast Cancer 2020;6:54. https://doi.org/10.1038/s41523-020-00197-2. PMID: 33088912; PMCID: PMC7568552.

2. Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer 2019;19(1):202.
Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5. PMID: 32517735; PMCID: PMC7285581.

[3] Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Feb 8 Nat Rev Clin Oncol 2021. https://doi.org/10.1038/s41571-021-00470-8. Epub ahead of print. PMID: 33558752.

[4] Bardia A, Hurwitz SA, Tolany SM, et al. ASCENT clinical trial investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. Apr 22 N Engl J Med 2021;384(16):1529–41. https://doi.org/10.1056/NEJ-moa2028485. PMID: 33882206.

[5] Tarantino P, Hamilton E, Tolany SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 2020;38(17):1951–62. https://doi.org/10.1200/JCO.19.02488.

[6] Barroso-Sousa R, Tolany SM. Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond. BioDrugs 2021;35(2):159–74. https://doi.org/10.1007/s40259-021-00472-2.

[7] Esposito M, Ganesan S, Kang Y. Emerging strategies for treating metastasis. Nat Can 2021;2:258–70. https://doi.org/10.1038/s42188-021-00181-0.

[8] Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenshine G, Blohmner J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eifftmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets I, Tang S, Gerber B, Geyer Jr CE, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Jul 12 Lancet 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Erratum in: Lancet. 2019 Mar 9;393(10175):986. PMID: 24529560.

[9] von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Scherwich A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnr IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wufing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowskis D, Smitt M, Douthwaite H, Singel SM, Geyer CE, KATHERINE investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. Feb 14 N Engl J Med 2019;380(7):617–28. https://doi.org/10.1056/NEJ-moa1814017. Epub 2018 Dec 5. PMID: 30516102.

[10] Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges. Cancers 2020;12(6):1404. https://doi.org/10.3390/cancers12061404. Published 2020 May 29.